Investors

Press Releases

June 15, 2022

AREV Life Sciences announces acceleration of the clinical development of SUSTAINN, as further predictions of global famine increase demand for Ready to Use Therapeutic Foods (RUTF’s)

May 27, 2022

AREV Life Sciences issues retention warrants

April 21, 2022

AREV Life Sciences Global Corporation announces engagement of TransBIOTech to facilitate preclinical therapeutic pipeline development

April 19, 2022

Brian V. Elliott Joins Arev Life Sciences Global Corporation

April 8, 2022

Kevin Phelps, CPA Appointed Chief Operating Officer of Arev Life Sciences Global Corporation & Warrant Offering

March 10, 2022

AREV Life Sciences enters Into Collaboration Agreement with Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba

February 23, 2022

AREV Life Sciences Completes Lab and Fungi Fruiting Room Build

February 17, 2022

AREV Life Sciences Advances Developments, New Appointments, and Relationships

January 18, 2022

AREV SAB member Richard Van Breeman PhD publishes landmark study on CoVid19

December 23, 2021

AREV Life Sciences appoints Allan Echino as Director and Denby Greenslade as interim CFO

December 9, 2021

AREV Life Sciences Settles Pending Litigation with Harvey

December 2, 2021

AREV Life Sciences / Absolem JV Receives Extraction Results

November 30, 2021

AREV Acquires Wright & Well Essentials Inc

November 8, 2021

AREV LIFE SCIENCES GLOBAL CORP ANNOUNCES STOCK OPTION GRANT

September 7, 2021

AREV Signs Definitive Collaborative Development Agreement with Voynich Biosciences and Invites Richard van Breemen PhD to SAB REVISED RELEASE first issued July 28, 2021

September 2, 2021

AREV Announces Brian Cameron as Chief Financial Officer

August 13, 2021

AREV Changes their name to AREV Life Sciences Global Corp

July 29, 2021

AREV Signs Definitive Collaborative Development Agreement with Voynich Biosciences and Invites Richard van Breemen PhD to SAB

July 22, 2021

Data Presented at the 11th IAS Conference on HIV Science Supports AREV’s Development of SUS-TAINN™, a Ready-to-Use Therapeutic Food to Treat Global Malnutrition and Starvation

July 6, 2021

AREV Expands Operations to Rochester New York Establishing Wholly Owned U.S. Subsidiary, AREV Life Sciences, Inc.